Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy

NARecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

September 1, 2026

Study Completion Date

December 1, 2026

Conditions
Psoriatic Arthritis
Interventions
DRUG

Guselkumab

This is a longitudinal study consisting of a two-time visit by psoriatic arthritis patients. The aim of the study is to determine the effect of biological therapies in liver disorders in patients with psoriatic arthritis.

Trial Locations (1)

92037

RECRUITING

University of California, San Diego, San Diego

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

University of California, San Diego

OTHER